Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Decheng Capital LLC (CIK 2010850) reported $661.3M across 14 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: CGON ($431.2M, 65.21%), NUVB ($111.3M, 16.84%), UPB ($24.5M, 3.71%), ACRS ($15.2M, 2.29%), AARD ($14.8M, 2.23%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | CGON | CG ONCOLOGY INC | $431.2M | 65.21% | 6.4M | Hold |
| 2 | NUVB | Nuvation Bio Inc. | $111.3M | 16.84% | 26.0M | Hold |
| 3 | UPB | Upstream Bio Inc. | $24.5M | 3.71% | 2.7M | Trimmed |
| 4 | ACRS | Aclaris Therapeutics, Inc. | $15.2M | 2.29% | 4.0M | Hold |
| 5 | AARD | AARDVARK THERAPEUTICS INC | $14.8M | 2.23% | 3.9M | Hold |
| 6 | LYEL | Lyell Immunopharma, Inc. | $13.9M | 2.10% | 692,050 | Hold |
| 7 | NAMS | NEWAMSTERDAM PHARMA CO NV | $10.4M | 1.57% | 325,057 | Trimmed |
| 8 | RCUS | Arcus Biosciences, Inc | $10.3M | 1.56% | 477,819 | Trimmed |
| 9 | RVMD | REVOLUTION MEDICINES INC(NSM) | $9.1M | 1.37% | 93,500 | Trimmed |
| 10 | EQ | Equillium Inc. | $8.9M | 1.34% | 4.4M | Hold |
| 11 | BYSI | BeyondSpring Inc. | $6.2M | 0.94% | 3.8M | Hold |
| 12 | ZNTL | Zentalis Pharmaceuticals Inc. | $3.1M | 0.47% | 1.3M | Hold |
| 13 | KRYS | KRYSTAL BIOTECH INC | $1.9M | 0.29% | 7,300 | Trimmed |
| 14 | PYXS | Pyxis Oncology, Inc (formerly Apexigen) | $477,143 | 0.07% | 326,810 | Hold |
| 15 | AURA | Aura Biosciences, Inc. | $0 | 0.00% | 0 | Exited |
| 16 | CRNX | CRINETICS PHARMACEUTICALS IN | $0 | 0.00% | 0 | Exited |
| 17 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $0 | 0.00% | 0 | Exited |
| 18 | NUVB/WS | Nuvation Bio Inc. | $0 | 0.00% | 0 | Exited |
| 19 | RZLT | REZOLUTE INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31